CD274 and cancer: This lack of efficacy may be associated with an increase of PD-L1 expression on cancer cells, elevated numbers of tumor-infiltrating immune cells in the tumor microenvironment, cancer cells with microsatellite instability or a mismatch-repair deficiency, cancers with an increased mutational burden and/or the existence of neoantigens56.